Literature DB >> 23731493

How academic labs can approach the drug discovery process as a way to synergize with big pharma.

Arianna Loregian1, Giorgio Palù.   

Abstract

While the pharmaceutical industry is facing highly challenging times, the academic drug discovery sector has the potential to contribute meaningfully to the discovery of novel drug targets and to the development of new mode-of-action therapeutics against a range of diseases, including rare and neglected diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Mesh：

Year:  2013        PMID： 23731493     DOI： 10.1016/j.tim.2013.03.006

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  9 in total

Review 1.  Mitigating risk in academic preclinical drug discovery.

Authors:  Jayme L Dahlin; James Inglese; Michael A Walters
Journal:  Nat Rev Drug Discov       Date:  2015-04       Impact factor: 84.694

Review 2.  Antiviral strategies against influenza virus: towards new therapeutic approaches.

Authors:  Arianna Loregian; Beatrice Mercorelli; Giulio Nannetti; Chiara Compagnin; Giorgio Palù
Journal:  Cell Mol Life Sci       Date:  2014-04-04       Impact factor: 9.261

3.  Helping science and drug development to succeed through pharma-academia partnerships: Yale Healthcare Conference 2013.

Authors:  Daniel X Yang; Yunsoo A Kim
Journal:  Yale J Biol Med       Date:  2013-09-20

4.  Towards personalized agriculture: what chemical genomics can bring to plant biotechnology.

Authors:  Michael E Stokes; Peter McCourt
Journal:  Front Plant Sci       Date:  2014-07-11       Impact factor: 5.753

5.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

Review 6.  Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.

Authors:  Andrés Pizzorno; Blandine Padey; Olivier Terrier; Manuel Rosa-Calatrava
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

Review 7.  Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Authors:  Beatrice Mercorelli; Giorgio Palù; Arianna Loregian
Journal:  Trends Microbiol       Date:  2018-05-11       Impact factor: 17.079

8.  Identification of Anti-Mycobacterium and Anti-Legionella Compounds With Potential Distinctive Structural Scaffolds From an HD-PBL Using Phenotypic Screens in Amoebae Host Models.

Authors:  Nabil Hanna; Sébastien Kicka; Gianpaolo Chiriano; Christopher Harrison; Hajer Ouertatani Sakouhi; Valentin Trofimov; Agata Kranjc; Jahn Nitschke; Marco Pagni; Pierre Cosson; Hubert Hilbi; Leonardo Scapozza; Thierry Soldati
Journal:  Front Microbiol       Date:  2020-02-21       Impact factor: 5.640

Review 9.  Improving target assessment in biomedical research: the GOT-IT recommendations.

Authors:  Christoph H Emmerich; Lorena Martinez Gamboa; Martine C J Hofmann; Marc Bonin-Andresen; Olga Arbach; Pascal Schendel; Björn Gerlach; Katja Hempel; Anton Bespalov; Ulrich Dirnagl; Michael J Parnham
Journal:  Nat Rev Drug Discov       Date:  2020-11-16       Impact factor: 112.288
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.